OS Therapies (OSTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

OSTX OS Therapies

Watchlist

2.060
+0.060+3.00%

Close Nov 27 16:00 ET

1.820
-0.240-11.65%

Post 20:02 ET

43.75MMarket Cap-5885P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

OS Therapies Analyst Ratings
BenzingaNov 26 09:53 ET · Ratings
Maxim Group Initiates OS Therapies(OSTX.US) With Buy Rating, Announces Target Price $8
Moomoo NewsNov 26 08:31 ET · Ratings
Express News | Os Therapies : Maxim Group Initiates Coverage With Buy Rating; Target Price $8
ReutersNov 26 07:38 ET
OS Therapies | 8-K: OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
SECNov 15 16:09 ET
OS Therapies 3Q Loss/Shr 18c >OSTX
Dow JonesNov 15 09:50 ET
Express News | OS Therapies Q3 EPS $(0.18) Misses $(0.12) Estimate
BenzingaNov 15 09:49 ET

Comments

Jaguar8

Sep 11 07:18

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer
Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer
Strong safety profile for FRA-H wit...

Jaguar8

Aug 29 06:53

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...